Form 4: Myriad Genetics CEO Paul Diaz Reports Stock Transactions

Paul Diaz, President and CEO of Myriad Genetics, reports acquisition of stock units and disposition of shares to cover tax obligations.

Summary

• Paul J. Diaz, the President and CEO of Myriad Genetics, filed a Form 4 detailing changes in beneficial ownership.
• On March 14, 2024, Diaz acquired 246,248 shares of common stock at $0, representing time-based restricted stock units vesting.
• These restricted stock units vest in three equal annual installments starting on the first anniversary of the grant date.
• On March 15, 2024, Diaz disposed of 30,610 shares at $21.16 to cover tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Diaz beneficially owns 1,360,034 shares of Myriad Genetics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations. There is no indication of unusual or concerning activity.

Positives

• The acquisition of restricted stock units indicates confidence in the company's future performance.

Negatives

• The sale of shares to cover tax obligations, while routine, slightly reduces the CEO's holdings.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing indicates standard compensation practices involving restricted stock units and tax withholding.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates